New data shows promising potential of ABBV-706 for neuroendocrine tumor treatment
In groundbreaking research presented by PharmExec, the latest data on ABBV-706 reveals promising outcomes for patients battling neuroendocrine tumors. ABBV-706, a targeted therapy, has shown